← Leaderboards
Arun K Ghosh
University Of Illinois At Chicago
$14,662,368
Attributed
$18,271,855
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,271,855 · 8
By mechanism
R01$11,927,182 · 5
R37$4,872,943 · 2
P01$1,471,730 · 1
Top collaborators
- Laura D. Kramer5 shared
- Hongmin Li5 shared
- Andrew D Mesecar4 shared
Most similar at University Of Illinois At Chicago
Same institution · by research overlap
- Andrew D Mesecar$12,210,126
- Kyuyeon Han$1,638,975
Others in their field
Top investigators on “Drug Resistance”
- Judith S. Currier · University Of California Los Angeles$207,752,958
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$145,910,108
- Ralph Parchment · Leidos Biomedical Research, Inc.$140,676,376
- Daniel R Kuritzkes · Brigham And Women'S Hospital$114,882,802
- Peter C Adamson · National Childhood Cancer Foundation$114,476,581
- Wafaa M. El-Sadr · Columbia University Health Sciences$113,453,088
Research focus
Drug ResistanceProtease InhibitorDesignRoentgen RaysStructureVirusToxic EffectAntiviral AgentsCellsFutureGenerationsInsightMolecularBaseBiologicalLigandsUncertaintyComplexViralResistance ProfileDrug DesignPeptide HydrolasesMolecular ModelingInhibitor/Antagonist
Grant awards (46)
SARS-CoV-2 protease inhibitors for treating COVID-19$750,974
R01 · FY2025 · AI · contact PI
Design & Synthesis of Nonpeptide Protease Inhibitors$591,403
R01 · FY2025 · AI · contact PI
Design & Synthesis of Nonpeptide Protease Inhibitors$580,003
R01 · FY2024 · AI · contact PI
SARS-CoV-2 protease inhibitors for treating COVID-19$750,974
R01 · FY2023 · AI · contact PI
Design & Synthesis of Nonpeptide Protease Inhibitors$608,503
R01 · FY2023 · AI · contact PI
SARS-CoV-2 protease inhibitors for treating COVID-19$750,974
R01 · FY2022 · AI · contact PI
SARS-CoV-2 protease inhibitors for treating COVID-19$750,974
R01 · FY2021 · AI · contact PI
Design & Synthesis of Nonpeptide Protease Inhibitors$484,067
R37 · FY2020 · AI · contact PI
Design & Synthesis of Nonpeptide Protease Inhibitors$485,149
R37 · FY2019 · AI · contact PI
Design & Synthesis of Nonpeptide Protease Inhibitors$486,203
R37 · FY2018 · GM · contact PI
Design & Synthesis of Nonpeptide Protease Inhibitors$492,407
R37 · FY2017 · GM · contact PI
Design & Synthesis of Nonpeptide Protease Inhibitors$510,574
R37 · FY2016 · GM · contact PI
Design & Synthesis of Nonpeptide Protease Inhibitors$100,000
R37 · FY2016 · GM · contact PI
Inhibition and mechanism of flavivirus methyltransferase$635,641
R01 · FY2015 · AI
Design & Synthesis of Nonpeptide Protease Inhibitors$480,010
R37 · FY2015 · GM · contact PI
Inhibition and mechanism of flavivirus methyltransferase$635,641
R01 · FY2014 · AI
Design & Synthesis of Nonpeptide Protease Inhibitors$475,402
R37 · FY2014 · GM · contact PI
Design & Synthesis of Nonpeptide Protease Inhibitors$49,918
R37 · FY2014 · GM · contact PI
Inhibition and mechanism of flavivirus methyltransferase$597,502
R01 · FY2013 · AI
Design & Synthesis of Nonpeptide Protease Inhibitors$455,083
R37 · FY2013 · GM · contact PI
Inhibition and mechanism of flavivirus methyltransferase$661,641
R01 · FY2012 · AI
Design & Synthesis of Nonpeptide Protease Inhibitors$358,713
R37 · FY2012 · GM · contact PI
Design & Synthesis of Nonpeptide Protease Inhibitors$133,125
R37 · FY2012 · GM · contact PI
Inhibition and mechanism of flavivirus methyltransferase$630,883
R01 · FY2011 · AI
Design & Synthesis of Nonpeptide Protease Inhibitors$362,292
R37 · FY2011 · GM · contact PI
DESIGN AND SYNTHESIS OF NONPEPTIDE PROTEASE INHIBITORS$340,080
R01 · FY2010 · GM · contact PI
DESIGN AND SYNTHESIS OF NONPEPTIDE PROTEASE INHIBITORS$366,206
R01 · FY2009 · GM · contact PI
Design & Synthesis of SARS Protease Inhibitors$312,714
P01 · FY2009 · AI · contact PI
DESIGN AND SYNTHESIS OF NONPEPTIDE PROTEASE INHIBITORS$213,216
R01 · FY2009 · GM · contact PI
DESIGN AND SYNTHESIS OF NONPEPTIDE PROTEASE INHIBITORS$430,155
R01 · FY2008 · GM · contact PI
Design & Synthesis of SARS Protease Inhibitors$303,848
P01 · FY2008 · AI · contact PI
DESIGN AND SYNTHESIS OF NONPEPTIDE PROTEASE INHIBITORS$32,393
R01 · FY2008 · GM · contact PI
DESIGN AND SYNTHESIS OF NONPEPTIDE PROTEASE INHIBITORS$32,393
R01 · FY2008 · GM · contact PI
DESIGN AND SYNTHESIS OF NONPEPTIDE PROTEASE INHIBITORS$344,764
R01 · FY2007 · GM · contact PI
Design & Synthesis of SARS Protease Inhibitors$300,856
P01 · FY2007 · AI · contact PI
Design & Synthesis of SARS Protease Inhibitors$273,988
P01 · FY2006 · AI · contact PI
Design and Synthesis of Nonpeptide Protease Inhibitors$314,828
R01 · FY2005 · GM
Design &Synthesis of SARS Protease Inhibitors$280,324
P01 · FY2005 · AI
Design and Synthesis of Nonpeptide Protease Inhibitors$305,354
R01 · FY2004 · GM
Design and Synthesis of Nonpeptide Protease Inhibitors$369,347
R01 · FY2003 · GM
Design and Synthesis of Nonpeptide Protease Inhibitors$47,340
R01 · FY2003 · GM
Design and Synthesis of Nonpeptide Protease Inhibitors$344,296
R01 · FY2002 · GM
DESIGN AND SYNTHESIS OF NONPEPTIDE PROTEASE INHIBITORS$260,142
R01 · FY2001 · GM
DEVELOPMENT OF LIGAND ASSISTED ASYMMETRIC SYNTHESES$165,480
R01 · FY2001 · GM
DESIGN AND SYNTHESIS OF NONPEPTIDE PROTEASE INHIBITORS$253,904
R01 · FY2000 · GM
DEVELOPMENT OF LIGAND ASSISTED ASYMMETRIC SYNTHESES$162,171
R01 · FY2000 · GM